Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383383 | 0.87 | HRH3 (0.61) | HRH3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL522002 | 0.85 | CHRNA7 (0.61) | HRH3CHRNA7ALDH1A1MEN1LMNA | |
| SCHEMBL4387836 | 0.85 | HRH3 (0.46) | GPR183HRH3DRD3CHRNA7ALDH1A1 | |
| SCHEMBL20645773 | 0.83 | HRH3 (0.46) | GPR183HRH3DRD3KDM4EALDH1A1 | |
| SCHEMBL13447875 | 0.82 | BLM (0.62) | DRD3KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL3919943 | 0.82 | HRH3 (0.56) | GPR183HRH3DRD3KDM4ECHRNA7 | |
| SCHEMBL3920077 | 0.81 | CHRNA7 (0.67) | HRH3CHRNA7ALDH1A1MEN1LMNA | |
| SCHEMBL2050814 | 0.80 | ALDH1A1 (0.50) | GPR183HRH3CHRNA7ALDH1A1MEN1 | |
| SCHEMBL2041678 | 0.79 | CYP2D6 (0.53) | HRH3DRD3ALDH1A1MEN1LMNA | |
| SCHEMBL1177293 | 0.78 | HRH3 (0.78) | HRH3DRD3KDM4ECHRNA7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558595-B1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-25 | — | — | EP | disclosed |
| EP-1558595-B1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-25 | — | — | EP | disclosed |
| CN-100558718-C | Piperazinyl and diazacyclo heptyl benzene methane amide and thiobenzamide | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-11 | — | — | CN | disclosed |
| US-7414047-B2 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-7414047-B2 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-7414047-B2 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | APODACA RICHARD L | 2008-03-06 | — | — | US | disclosed |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | APODACA RICHARD L | 2008-03-06 | — | — | US | disclosed |
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | APODACA RICHARD L | 2008-03-06 | — | — | US | disclosed |
| CN-1729180-A | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | CN | disclosed |
| EP-1558595-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004037801-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056991-A1 | PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES | HRH2, HNMT, HRH3 | GPR183 3162/4885HRH3 3/4885DRD3 2332/4885 |
| US-20040110746-A1 | Piperazinyl and diazapanyl benzamides and benzthioamides | HRH2, HNMT, HRH3 | GPR183 3162/4885HRH3 3/4885DRD3 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.